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Dynamin I is a key molecule required for the recycling
of synaptic vesicles in neurons, and it has been known
that dynamin I gene expression is induced during neu-
ronal differentiation. Our previous studies established
that neuronal restriction of dynamin I gene expression
is controlled by Sp1 and nuclear factor-B-like ele-
ment-1. Here, using a series of deletion constructs and
site-directed mutation, we found that transcription of
dynamin I gene during neuronal differentiation of N1E-
115 cells is controlled primarily by the Sp1 element lo-
cated between 13 to 4 bp of the dynamin I promoter.
Gel shift analysis demonstrated that in addition to Sp1,
Sp3 could interact with this Sp1 element. The require-
ment for Sp family transcription factors in dynamin I
gene expression was confirmed by using mithramycin,
an inhibitor of Sp1/Sp3 binding. Mithramycin repressed
dynamin I gene expression and resulted in blocking of
neuronal differentiation of N1E-115 cells. The localiza-
tion of the dynamin I protein was also restricted in the
peripheral region of the nucleus by the mithramycin
treatment. Thus, all of our results suggest that induction
of dynamin I gene expression during N1E-115 cell differ-
entiation is modulated by Sp1/Sp3 interactions with the
dynamin I promoter, and its expression is important for
neuronal differentiation of the N1E-115 cells.
Dynamin is a GTPase protein that is believed to play a key
role in detaching clathrin-coated vesicles from the plasma
membrane (1, 2). The role of dynamin in receptor-mediated
endocytosis in mammalian cells has been confirmed both in
vivo and in vitro (3–6), but its exact function remains contro-
versial (7, 8). In brain, three different isoforms of dynamin
(brain-specific dynamin I (9, 10), ubiquitously expressed dy-
namin II (11), and dynamin III that was originally described as
being testis-specific (12)) are expressed simultaneously. It has
been known that the mRNA levels of dynamin I and III are
up-regulated throughout brain development, whereas the lev-
els of dynamin II mRNA remain unchanged (12, 13). Therefore,
understanding the regulation mechanism that confers cell
type- and development stage-specific expression of dynamin I is
important to know the in vivo role of this protein. To under-
stand the molecular mechanism of tissue-specific dynamin I
gene expression, we previously cloned and analyzed the 5-
flanking regions of the mouse dynamin I gene and reported
that Sp1, NF-B-like element (NE)1-1, and neuron restrictive
silencer element are required for the promoter activity of dy-
namin I gene in neuronal cells (14, 15). We also reported that
YY1 binds to the negative regulatory region of the dynamin I
gene promoter and strongly represses dynamin I promoter
activity (16).
The N1E-115 neuroblastoma cells are capable of forming
neurites when grown in the absence of serum or in the presence
of Me2SO (17–19). Previously, Torre et al. reported that dy-
namin I levels increase steadily with the formation of neurites
and decrease during the serum-induced neurite retraction in
the N1E-115 cells (20). Furthermore, a reduction in the intra-
cellular level of dynamin in the hippocampal neurons through
antisense oligonucleotide treatment results in a significant
impairment in neurite formation. Therefore, these results pro-
vided convincing evidence demonstrating that dynamin I is
required for normal neuritogenesis.
To study the molecular mechanism of the up-regulation of
dynamin I gene expression during the differentiation of N1E-
115 cells, we analyzed the promoter activity of the dynamin I
gene in this cell. Deletion analysis in conjunction with site-
directed mutagenesis showed that an Sp1 site at 14 to 7 is
critical for Me2SO-induced dynamin I promoter activity. Gel
shift analysis demonstrated that in addition to Sp1, Sp3 could
interact with this Sp1 element. We also confirmed that Sp
family transcription factors are functionally important since
mithramycin, an inhibitor of Sp1/Sp3 binding (21), represses
dynamin I gene expression. Furthermore, a reduction in the
intracellular level of dynamin I in N1E-115 cells through mith-
ramycin treatment resulted in a significant impairment in
neurite formation. These results provide evidence that the dy-
namin I gene is transcriptionally activated during Me2SO-
induced neuronal differentiation of N1E-115 cells through an
Sp1 element, and this activation is essential for neuronal dif-
ferentiation of the N1E-115 cells.
EXPERIMENTAL PROCEDURES
Reporter Plasmid Construction and Transient Transfection Proce-
dure—All of the deletion and mutant constructs of the dynamin I
promoter used in this study were previously described (14).
Cell Culture and Transient Transfection Assay—N1E-115 cells were
passaged in Dulbecco’s modified Eagle’s medium containing 4.5 g of
glucose/liter and supplemented with 10% fetal bovine serum and 2 mM
glutamine. All culture media contained 100 units of penicillin and 100
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g/ml streptomycin. Cells were subcultured from confluent dishes by
diluting the cells 1:4 with fresh medium 3 days prior to transfection. All
of the dynamin I promoter constructs were transfected into N1E-115
cells by means of FuGENE 6 (Roche Molecular Biochemicals). The cells
were allowed to adhere to the dish for 12 h; 1.5% Me2SO was added to
one dish of each pair, and the cells were incubated for an additional
48 h.
CAT and -Galactosidase Assays—To prepare cell extracts for CAT
and -galactosidase expression assay, cells were scraped and centri-
fuged at 4 °C for 5 min. The cell pellet was resuspended in 150 l of 0.25
M Tris, pH 7.8, and then subjected to three freeze-thaw cycles. Cell
debris was centrifuged at 4 °C for 5 min. The resulting supernatant was
removed and used directly in the assays. -Galactosidase assay was
carried out using a chlorophenol red--D-galactopyranoside (Roche Mo-
lecular Biochemicals) and used to normalize CAT activities. -Galacto-
sidase activity was measured using 10 l of cell extract in a reaction
mixture consisting of 2.5 mM chlorophenol red--D-galactopyranoside
and 1.25 mM MgCl2. After incubation for 0.5–1 h at 37 °C, the reaction
was stopped by the addition of 3 mM ZnCl2, and the absorbance of
reaction product was read at 574 nm. CAT activity was determined
using 50–100 l of cell extract in the presence of acetyl-CoA and
[14C]chloramphenicol in a total volume of 150 l. The mixture was
incubated at 37 °C for 2 h, extracted with ethyl acetate, and dried in a
vacuum desiccator. Acetylated and non-acetylated forms of [14C]chlor-
amphenicol were resuspended in 20 l of ethyl acetate and separated by
thin-layer chromatography for 30 min at room temperature with chlo-
roform/methanol (97:3, v/v) as the mobile phase. Percentage conversion
of chloramphenicol to its acetylated forms was determined using
phosphorimaging.
Reverse Transcription-PCR—Total RNA was prepared from N1E-115
cells grown either in the presence or absence of Me2SO. Mithramycin
(200 nM) was cotreated with Me2SO for 48 h. Five micrograms of total
RNA were mixed with 300 ng of oligo(dT) primer and heated at 65 °C for
5 min, cooled slowly at room temperature, and then reverse transcribed
using StrataScript reverse transcriptase (Stratagene) at 42 °C for 1 h as
recommended by the supplier. One-tenth of the reverse-transcribed
mixture was PCR-amplified using forward primer 5-TCTGAAGCT-
GCGTGATGTG-3 (1694 to 1713) and reverse primer 5-CATC-
GAGTGCATGAAGCTGT-3 (1941 to 1922) relative to the first ATG
in the coding sequence of the dynamin I gene. Thirty cycles of PCR were
done at 94 °C for 1 min, 53 °C for 1 min, and 72 °C for 1 min.
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift
Assay—N1E-115 cells were propagated as described for transfection
analysis and treated with 1.5% Me2SO or grown under control condi-
tions in 15-cm dishes. The cells were washed with ice-cold phosphate-
buffered saline (PBS) and resuspended in 1 ml of lysis buffer (10 mM
HEPES, pH 7.9, 1.5 mM MgCl2). The cells were incubated on ice for 15
min, and the nuclei were then pelleted by centrifugation for 15 min at
3000  g at 4 °C. The pellet was resuspended in 200 l of extraction
buffer (30 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.2 mM dithiothreitol, 1
mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, leupeptin, 500
mM KCl, 10% glycerol). The cells were incubated on ice for 30 min and
pelleted by centrifugation for 20 min at 12,000  g at 4 °C. The super-
natant was recovered as the nuclear extract and protein concentrations
were determined by a modified Bradford method (Bio-Rad). For elec-
trophoretic mobility shift assay, 8 g of nuclear extract proteins were
mixed with the binding buffer (30 mM HEPES, pH 7.9, 1.5 mM MgCl2,
0.2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml
aprotinin,leupeptin, 100 mM KCl, 10% glycerol, 0.5 g of poly(dI-dC)).
Double stranded 32P-labeled oligonucleotides containing an Sp1 se-
quence were used as a probe. In the competition experiments, a 100-fold
molar excess of unlabeled oligomers (wild and mutated Sp1 oligonucleo-
tides) were incubated with the nuclear extracts before addition of 32P-
labeled oligonucleotides. For supershift analysis, 1 l of antibody spe-
cific for Sp1, Sp2, Sp3, or Sp4 (Santa Cruz Biotechnology) was
preincubated with nuclear extract proteins for 1 h at 4 °C before addi-
tion of the DNA probe. To block Sp1 binding to DNA, DNA probes were
preincubated for 1 h at 4 °C with mithramycin (200 nM) before being
used in binding reactions. Protein/DNA complexes were fractionated by
electrophoresis in nondenaturing 5% polyacrylamide gels for normal
EMSA experiments or in nondenaturing 4% polyacrylamide gels for
supershift analysis and visualized by autoradiography.
Light Microscopy, Confocal Laser Scanning Microscopy, and Data
Analysis—The formation of neurites in N1E-115 cells by Me2SO treat-
ment and blocking of neurites formation by different concentration of
mithramycin (100–300 nM) treatment were monitored by inverted mi-
croscopy (Axiovert 25 microscope, Zeiss). Pictures were taken after 48 h
of each treatment. For immunofluorescence assay, N1E-115 cells
treated with different concentration of mithramycin were grown on
glass coverslips for 48 h to 60% confluence. The coverslips were rinsed
briefly in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4, pH 7.4) and fixed for 20 min at room temperature in 4%
paraformaldehyde fixative, followed by permeabilization with 0.1% Tri-
ton X-100. The cells were blocked with 1.0% bovine serum albumin in
PBS and incubated for 1 h at room temperature with monoclonal
antibody against dynamin I (BD Transduction Laboratories) as primary
antibody diluted in PBS containing 1.0% bovine serum albumin. After
three washes in PBS, the coverslips were incubated with affinity-iso-
lated secondary antibody (fluorescein-conjugated goat anti-mouse IgG)
(BIOSOURCE, Camarillo, CA). The coverslips were washed three times
with PBS and mounted in fluorescent mounting medium (DAKO). Cells
were observed for epifluorescence using a confocal laser scanning mi-
croscope (TCS400, LEICA, Inc.). Acquired images were manipulated
with SCANware 5.0 (LEICA, Inc.) and digitized using Adobe PhotoShop
Software (Adobe Photosystems, Inc., Mountain View, CA). All data are
depicted as mean S.E. Differences between two groups were validated
by Student’s t test.
FIG. 1. Characterization of the Me2SO-inducible regions of the dynamin I promoter in N1E-115 cells. A series of deletion constructs
(left) were cotransfected with a pCMV- standardization plasmid into N1E-115 cells, and the cells were either grown under control condition
(middle, white bars) or in the presence of 1.5% Me2SO (middle, black bars) for 48 h. The cells were harvested, extracts were prepared, CAT and
-galactosidase activities were determined, and -galactosidase activity was used to correct for variations in transfection efficiency. The promoter
activities of each dynamin I-CAT fusion constructs were determined and expressed as a fold of CAT activity of the pCAT-Basic. Fold of induction
was calculated by dividing the corrected induced value by the corrected control value (right). The results, expressed as mean S.E., represent data
obtained in three independent experiments. Asterisks indicate statistically significant induction in the presence of 1.5% Me2SO as determined by
Student’s t test (p  0.05).
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RESULTS
Cis-acting Elements for Me2SO-induced Dynamin I Promoter
Activity in N1E-115 Neuroblastoma Cells—It has been known
that the dynamin levels increase during neurite formation in
N1E-115 cells. To examine whether the activity of the mouse
dynamin I promoter we previously cloned is activated during
neurite formation, pCATIP931 containing a 931-bp 5-flanking
sequence of the mouse dynamin I gene (931-105) fused to
the promoterless CAT gene in pCAT-Basic was transfected in
N1E-115 cells, and the cells were either grown under control
conditions or treated with 1.5% Me2SO for 48 h. To control for
variations in transfection efficiency, pCMV plasmid was co-
transfected, and -galactosidase activity was used to standard-
ize CAT activity. As seen in Fig. 1, Me2SO treatment resulted
in a 4-fold increase in dynamin I promoter activity.
To determine the region that is responsible for this induc-
tion, progressive 5 deletion mutants of the dynamin I promoter
were constructed, and their promoter activities were assayed in
N1E-115 cells (Fig. 1). The response to Me2SO was maintained
through deletion to 31. However, extension of the 5 deletion
to nt 1 drastically abrogated the response. These results
indicate that the Me2SO regulatory region lies in the 30-bp
region located between 30 and 1.
Dynamin I Promoter Activity Is Regulated by the Transcrip-
tion Factors Sp1 and Sp3—To elucidate the molecular mecha-
nism by which expression of dynamin I is tissue specifically
regulated, we previously cloned and characterized the pro-
moter of mouse dynamin gene and reported that Sp1, NE-1,
and neuron-restrictive silencer element are required for the
promoter activity of dynamin I gene in neuronal cells (14, 15).
We also reported that YY1 has a negative role in regulation of
the dynamin I gene promoter activity (16). One Sp1 DNA
binding site is located in this Me2SO regulatory region (Fig.
2A). To define whether this element contributes to the response
to Me2SO, the Sp1 binding site was mutated, and the effect of
this mutation on promoter activity was determined. Mutation
of the Sp1 binding site in pCATIP30 nearly abrogated the
response to Me2SO (Fig. 2B). This result suggests that the Sp1
binding site is critical for the Me2SO-induced dynamin I pro-
moter activity.
To examine protein binding to this element, we used electro-
phoretic mobility shift assays with a radiolabeled Sp1 element
located in the Me2SO regulatory region as a probe and extracts
from N1E-115 cells either grown under control conditions or
treated with 1.5% Me2SO for 48 h. We found that this probe
specifically binds to protein complexes designated as C1 to C3
FIG. 2. Functional role of the Sp1 el-
ement in dynamin I promoter and
analysis by mutagenesis. A, schematic
diagram of the mouse dynamin I promoter.
Important cis-acting elements of dynamin I
promoter, which we previously published,
were shown. B, N1E-115 cells transiently
transfected with wild type (pCATIP30),
Sp1 mutant (pCATIP30mSp1), and control
vector were treated with 1.5% Me2SO for
48 h prior to lysis for CAT activity assays.
-Galactosidase activity was used to cor-
rect for variations in transfection effi-
ciency. The results, expressed as mean 
S.E., represent data obtained in three in-
dependent experiments.
FIG. 3. Sp1 and Sp3 bind to the dynamin I promoter. A, EMSA was performed with 8 g of nuclear extracts from N1E-115 cells that had
either been treated with 1.5% Me2SO (lanes 4–6) for 48 h or grown under control conditions (lanes 1–3). When the labeled Sp1 oligonucleotide was
used, three specific DNA/protein complexes (C1–C3) were formed (lanes 1 and 4). Competition analysis was performed in the presence of a 100-fold
molar excess of unlabeled Sp1 (lanes 2 and 5) and mSp1 (lanes 3 and 6) oligonucleotide. B, binding of Sp1 and Sp3 to probe Sp1 was analyzed by
supershift assay using anti-Sp1 and anti-Sp3 Abs. A nuclear extract form N1E-115 cells that had been treated with 1.5% Me2SO for 48 h was
incubated with indicated Abs and then mixed with 32P-labeled Sp1 probe. Complexes (C1–C3) with Sp1 or Sp3 and further shifted bands with
anti-Sp1 (lanes 2 and 4) and anti-Sp3 (lanes 3 and 4) Abs are indicated. C, supershift analysis was performed in the presence of anti-Sp2 (lane 3)
and anti-Sp4 (lane 4) Abs.
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from N1E-115 cells either grown under control conditions or
treated with 1.5% Me2SO (Fig. 3A). Complex formation was
inhibited specifically by adding excess amounts of unlabeled
Sp1 consensus oligonucleotide (lanes 2 and 5) but not by the
Sp1 mutant oligonucleotide (lane 3 and 6). To confirm that Sp1
binds to this element, we performed EMSA in the presence of
Sp family antibodies to demonstrate supershifting. An oligonu-
cleotide containing the Sp1 element located in the Me2SO reg-
ulatory region was incubated with nuclear extracts from N1E-
115 cells treated with 1.5% Me2SO and Sp1- and Sp3-specific
antibodies (Fig. 3B). Supershift assays demonstrated that com-
plex C1 disappeared with an anti-Sp1 Ab (lanes 2 and 4),
revealing a further shifted complex (lanes 2 and 4, Sp1 (C1)).
Complexes C2 and C3 also disappeared with the anti-Sp3 Ab
(lanes 3 and 4) with a new shifted complex appearing (lanes 3
and 4, Sp3 (C2)). Two complexes disappeared with the anti-Sp3
Ab, suggesting that this Ab binds to two different sized Sp3 as
described previously (22). However, only one further shifted
band was observed (lane 3, Sp3 (C2)). It is conceivable that a
further shifted band is located, and thus not detected, in the
same position as complex C1. Indeed, a weak band was ob-
served at the same position as C1 with anti-Sp1 and -Sp3 Abs
(lane 4, Sp3 (C3)). Incubation of the binding reactions with
either anti-Sp2 or anti-Sp4 antibodies did not affect the EMSA
pattern (Fig. 3C). All of these results suggested that Sp1 and
Sp3 bind to the Sp1 element spanning 13 to 4, and this
element is critical for the Me2SO-induced dynamin I promoter
activity.
Mithramycin Treatment Reduces Dynamin I Levels and Pre-
vents Neurite Formation—To further investigate the role of Sp
family on the regulation of dynamin I expression, we analyzed
the effects of mithramycin, a drug that modifies GC-rich re-
gions of the DNA and blocks Sp1 binding (21), on the expres-
sion of dynamin I in N1E-115 cells induced by Me2SO. As
shown in Fig. 4, Me2SO induced dynamin I gene expression
about 5-fold (Fig. 4, A, B, lane 2) but cotreatment of mithramy-
cin with Me2SO completely abolished the accumulation of dy-
namin I mRNA in Me2SO-induced N1E-115 cells (Fig. 4, A, B,
lane 3), which strongly suggests that Sp1 binding is essential
for dynamin I expression. In gel shift experiments performed in
the presence or absence of mithramycin, we confirmed that the
drug inhibited Sp1 and Sp3 binding to the Sp1 element span-
ning 13 to 4 (Fig. 5A). To confirm whether dynamin I
promoter activity is also repressed by treatment of mithramy-
cin, we determined dynamin I promoter activity in the presence
of mithramycin (Fig. 5B). Treatment of mithramycin with
Me2SO completely reduced pCATIP30 activity but not
pCATIP30mSp1 activity. These results clearly suggest that
mithramycin abolished dynamin I gene expression by repress-
ing the binding between Sp family transcription factors and the
Sp1 element in dynamin I promoter.
It has been known that normal levels of dynamin I are
necessary for the formation of neurites in cultured hippocam-
pal neurons. Therefore, we reduced the intracellular level of
dynamin I in N1E-115 cells by mithramycin treatment and
measured the effect on neurite outgrowth. As shown in Fig. 6,
the morphology of N1E-115 cells was altered dramatically in
FIG. 6. Treatment of mithramycin prevents neurite formation
during differentiation of N1E-115 cells. N1E-115 cells were treated
with Me2SO in the presence (c, 100 nM; d, 200 nM; e, 300 nM) or absence
(b and b1) of mithramycin for 48 h. a, cells were grown under control
condition. Mithramycin inhibits formation of neurites and cell growth
with a dose-dependent manner (closed arrows). Open arrows indicate
neurites. Magnifications of all images are X200 except b1 (X400).
FIG. 4. Mithramycin blocks the Me2SO-induced expression of
the dynamin I gene. A, N1E-115 cells were treated with Me2SO in the
presence (lane 3) or absence (lane 2) of mithramycin for 48 h. Total RNA
was isolated and analyzed for dynamin I and -actin mRNA levels by
reverse transcription-PCR. The location of the dynamin I and -actin
bands is shown. B, quantitative scanning densitometry of dynamin I
band relative to -actin bands from 4A. Each data point represents the
mean S.E., and data was obtained in three independent experiments.
FIG. 5. Mithramycin blocks Sp1/Sp3 binding and dynamin I
promoter activity. A, Sp1 oligonucleotide, spanning nt 13 to 4,
was preincubated in the presence of mithramycin (200 nM, lane 4) at
4 °C for 1 h and subsequently used in gel shift analysis with nuclear
extracts from N1E-115 cells that had been treated with 1.5% Me2SO for
48 h. Complexes (C1–C3) with Sp1 or Sp3 are indicated. B, effect of
mithramycin on dynamin I promoter activity. N1E-115 cells were trans-
fected with either pCATIP30 (lane 1) or pCATIP30mSp1 (lane 2) con-
struct and treated with Me2SO in the presence (white bars) or absence
(black bars) of mithramycin for 48 h. The cells were harvested, extracts
were prepared, CAT and -galactosidase activities were determined,
and -galactosidase activity was used to correct for variations in trans-
fection efficiency. Each data point represents the mean S.E., and data
was obtained in three independent experiments.
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the presence of increasing concentrations of mithramycin. In
the mithramycin-treated cells, a significant reduction in the
number and length of neurites was observed (Fig. 6, c–e). This
inhibitory effect on neurite outgrowth was dose-dependent. We
also observed that the localization of dynamin is restricted in
peripheral region of nuclear in mithramycin-treated cells (Fig.
7, c–e), whereas dynamin I proteins are dispersed in cytoplasm
and cell processes including neurites in differentiated cells
(Fig. 7b). All of these results definitely suggest that induction of
dynamin I gene expression and exact localization are critical
for neurite formation.
DISCUSSION
It has been known that dynamin I mRNA and protein levels
increase during differentiation of N1E-115 cells and that nor-
mal levels of dynamin I are necessary for the formation of
neurites (20). In this study we found that an Sp1 element
located between 13 to 4 bp of the dynamin I promoter is
responsible for a major part of dynamin I promoter activity
during differentiation of N1E-115 cells, and Sp3 as well as Sp1
bound to this element. We also confirmed the importance of the
Sp1 element by using mithramycin, a drug that modifies GC-
rich regions of the DNA and blocks Sp1/Sp3 binding. Treat-
ment of mithramycin inhibited Sp1 and Sp3 binding to the Sp1
element and completely abolished the accumulation of dy-
namin I mRNA and promoter activity in Me2SO-induced N1E-
115 cells, which strongly suggests that Sp1/Sp3 binding is
essential for dynamin I expression. Blocking of dynamin I gene
expression by mithramycin treatment resulted in a significant
reduction of neurite formation. The localization of dynamin
also changed from cytoplasm and cell processes including neu-
rites to peripheral region of nuclear. All of these results clearly
suggest that induction of dynamin I gene expression and exact
localization are critical for neurite formation.
Dynamin is a GTPase that plays a critical role in endocytosis.
Although the majority of studies implicate dynamin in endocy-
tosis, there are many evidences to suggest that dynamin may
play additional functions in cell physiology. Recently, many
observations also link dynamin to the actin cytoskeleton. When
the dynamin K44A mutant is overexpressed, the distribution of
actin stress fibers and cell shape are altered (5, 23). Dynamin
was shown to colocalize with filamentous actin at membrane
ruffles (24) and also detected at podosomes (25). They also
suggested that a direct functional link of dynamin to the actin
cytoskeleton exists (25). All of these results and our results are
convergent with those of recent studies reporting that dynamin
directly binds regulatory components of the actin cytoskeleton,
such as profilin (26), proteins of the syndapin/pacsin/FAP52
family (27–29), and cortactin (30).
Sp1 is a well characterized sequence-specific DNA-binding
protein that is important for transcription of many cellular and
viral genes that contain GC boxes in their promoters (31, 32).
Three Sp1-related transcription factors (Sp2, Sp3, and Sp4)
have been cloned. Sp2 does not recognize the same sequence as
Sp1, and Sp4 expression is restricted to the brain. Sp3, on the
other hand, is ubiquitously expressed and recognizes the same
sequence as Sp1. Although Sp1 appears to be almost exclu-
sively an activating transcription factor, Sp3 contains a tran-
scriptional repression domain and can act as a transcriptional
activator or repressor depending on the promoter and cell type
studied (33, 34). While Sp1 and Sp3 are ubiquitous nuclear
factors, the differences in the level of expression during differ-
ent stages of development (35, 36) or in varying cell types (36)
along with specific posttranslational modifications (37) are re-
sponsible for altering gene transcription in a development-
specific and cell-specific manner. In addition, despite its gen-
eral role in transcription of housekeeping genes, Sp1 has been
demonstrated to be involved in induced transcription of various
genes responding to different biological stimuli (38–40). How-
ever, total amounts of Sp1 and Sp3 proteins were not changed
regardless of the differentiation state of N1E-115 cells, and
they bound to the Sp1 element spanning 13 to 4 not only in
Me2SO-induced cells but also in control cells (Fig. 3A). It is still
possible that other Me2SO-inducible transcription factors
weakly bind to this element and enhance the promoter activity.
Another possibility is that binding of some Me2SO-inducible
transcription factors to their binding sites is dependent on the
interaction with Sp1 or Sp3. It has been reported that transient
interaction of Pur and Sp1 may result in stable association of
Pur to its binding element, and these factors synergistically
stimulate MBP promoter activity in central nervous system
cells (41). Therefore, further studies involving identification of
proteins that bind with Sp1 or Sp3 will facilitate elucidation of
the dynamin I gene expression.
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